Phio Pharmaceuticals announced the successful release of its first commercial-scale current Good Manufacturing Practice (cGMP) batch of PH-762 drug substance. This operational milestone confirms supply chain readiness and supports the planned initiation of a Phase 2b clinical trial in the first quarter of 2027. The validated drug substance will proceed to final drug product completion for use in the study targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Phio Pharmaceuticals is a clinical-stage biotechnology company developing cancer therapeutics using its proprietary INTASYL siRNA gene-silencing platform.
